41994-45-0

Basic information

• Product Name: Methyl 2-piperidinecarboxylate
• Synonyms: 2-piperidinecarboxylic acid methyl ester;methyl 2-piperidinecarboxylate;Methyl Piperidine-2-carboxylate;Methylpipecolinate;2-Piperidinecarboxylic;2-Piperidinecarboxylic acid methyl;2 - piperidine Methyl forMate
• CAS NO: 41994-45-0
• Molecular Formula: C₇H₁₃NO₂
• Molecular Weight: 143.18
• EINECS: 300-102-4
• Product Categories: Piperidine
• Mol File: 41994-45-0.mol

Chemical Properties

• Boiling Point: 193.8 °C at 760 mmHg
• Flash Point: 71 °C
• Appearance: /
• Density: 1.021 g/cm³
• Storage Temp.: Keep in dark place,Sealed in dry,Store in freezer, under -20°C
• PKA: 8.27±0.10(Predicted)
• CAS DataBase Reference: Methyl 2-piperidinecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-piperidinecarboxylate(41994-45-0)
• EPA Substance Registry System: Methyl 2-piperidinecarboxylate(41994-45-0)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36
• Hazardous Substances Data: 41994-45-0(Hazardous Substances Data)

Usage

Chemical Properties

White low melting solid

Upstream product

• 1723-00-8 (R)-(+)-pipecolic acid 
• 136788-42-6 (R)-2-[(1S,2S,5S)-2-Hydroxy-2,6,6-trimethyl-bicyclo[3.1.1]hept-(3Z)-ylideneamino]-6-iodo-hexanoic acid methyl ester 
• 113965-37-0 (R)-1-((S)-1-Phenyl-ethyl)-piperidine-2-carboxylic acid methyl ester 
• 262846-62-8 N-(2-methoxy-6-methylphenyl)pipecolic acid methyl ester 
• 67-56-1 methanol 
• 123-86-4 acetic acid butyl ester 
• 35677-83-9 methyl pipecolinate 
• 109-21-7 butyl butyrate 
• 371-27-7 2,2,2-trifluoroethylbutyrate 
• 67-63-0 isopropyl alcohol 
• 71-36-3 butan-1-ol 
• 123-20-6 vinyl n-butyrate 
• 406-95-1 2,2,2-trifluoroethyl acetate 
• 87184-80-3 5-tert-butyldimethylsilyloxypentanal 

Downstream Products

• 111479-14-2 methyl dl-N-acetylpipecolate 
• 19889-77-1 (RS)-piperidine-2-carboxamide 
• 108602-82-0 methyl Δ²-piperidine-2-carboxylate 
• 61700-55-8 pipecolic acid hydrazide 
• 118891-75-1 (S)-1-((S)-2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-piperidine-2-carboxylic acid methyl ester 
• 1054618-19-7 (S)-1-[(R)-6-((4S,6S)-6-Benzyloxymethyl-2,2-dimethyl-[1,3]dioxan-4-yl)-3-hydroxy-4-methyl-hexanoyl]-piperidine-2-carboxylic acid methyl ester 
• 92235-85-3 (S)-1-Phenylsulfanylmethyl-piperidine-2-carboxylic acid methyl ester 
• 1723-00-8 (R)-(+)-pipecolic acid 
• 132910-79-3 (+/-) methyl N-tert-butyloxycarbonyl 2-piperidinecarboxylate 
• 182343-54-0 1-(2-Bromo-benzoyl)-piperidine-2-carboxylic acid methyl ester 
• 124619-69-8 1-benzylpiperidine-2-carboxylic acid methyl ester 
• 186957-68-6 (S)-1-((7S,9S,10R)-10-Dibenzylamino-3-hydroxy-9-methoxy-7-triisopropylsilanyloxy-undecanoyl)-piperidine-2-carboxylic acid methyl ester 
• 35677-83-9 methyl (S)-pipecolinate 
• 35677-83-9 (+)-2R-Piperidine-2-carboxylic acid methyl ester 

Relevant articles and documents

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

Zirconium-hydride-catalyzed site-selective hydroboration of amides for the synthesis of amines: Mechanism, scope, and application

Developing mild and efficient catalytic methods for the selective synthesis of amines is a longstanding research objective. In this respect, catalytic deoxygenative amide reduction has proven to be promising but challenging, as this approach necessitates selective C–O bond cleavage. Herein, we report the selective hydroboration of primary, secondary, and tertiary amides at room temperature catalyzed by an earth-abundant-metal catalyst, Zr-H, for accessing diverse amines. Various readily reducible functional groups, such as esters, alkynes, and alkenes, were well tolerated. Furthermore, the methodology was extended to the synthesis of bio- and drug-derived amines. Detailed mechanistic studies revealed a reaction pathway entailing aldehyde and amido complex formation via an unusual C–N bond cleavage-reformation process, followed by C–O bond cleavage.

Design and Synthesis of 56 Shape-Diverse 3D Fragments

Fragment-based drug discovery is now widely adopted for lead generation in the pharmaceutical industry. However, fragment screening collections are often predominantly populated with flat, 2D molecules. Herein, we describe a workflow for the design and synthesis of 56 3D disubstituted pyrrolidine and piperidine fragments that occupy under-represented areas of fragment space (as demonstrated by a principal moments of inertia (PMI) analysis). A key, and unique, underpinning design feature of this fragment collection is that assessment of fragment shape and conformational diversity (by considering conformations up to 1.5 kcal mol?1 above the energy of the global minimum energy conformer) is carried out prior to synthesis and is also used to select targets for synthesis. The 3D fragments were designed to contain suitable synthetic handles for future fragment elaboration. Finally, by comparing our 3D fragments with six commercial libraries, it is clear that our collection has high three-dimensionality and shape diversity.

Discovery of γ-Lactam alkaloid derivatives as potential fungicidal agents targeting steroid biosynthesis

Biological control of plant pathogens is considered as one of the green and effective technologies using beneficial microorganisms or microbial secondary metabolites against plant diseases, and so microbial natural products have played important roles in the research and development of new and green agrochemicals. To explore the potential applications for natural γ-lactam alkaloids and their derivatives, 26 γ-lactams that have flexible substituent patterns were synthesized and characterized, and their in vitro antifungal activities against eight kinds of plant pathogens belonging to oomycetes, basidiomycetes, and deuteromycetes were fully evaluated. In addition, the high potential compounds were further tested using an in vivo assay against Phytophthora blight of pepper to verify a practical application for controlling oomycete diseases. The potential modes of action for compound D1 against Phytophthora capsici were also investigated using microscopic technology (optical microscopy, scanning electron microscopy, and transmission electron microscopy) and label-free quantitative proteomics analysis. The results demonstrated that compound D1 may be a potential novel fungicidal agent against oomycete diseases (EC50 = 4.9748 μg·mL-1 for P. capsici and EC50 = 5.1602 μg·mL-1 for Pythium aphanidermatum) that can act on steroid biosynthesis, which can provide a certain theoretical basis for the development of natural lactam derivatives as potential antifungal agents.

Furan-Derived Chiral Bicycloaziridino Lactone Synthon: Collective Syntheses of Oseltamivir Phosphate (Tamiflu), (S)-Pipecolic acid and its 3-Hydroxy Derivatives

A unified synthetic strategy for oseltamivir phosphate (tamiflu), (S)-pipecolic acid, and its 3-hydroxy derivatives from furan derived common chiral bicycloaziridino lactone synthon is described here. Key features are the short (4-steps), enantiopure, and decagram-scale synthesis of common chiral synthon from furan and its first-ever application in the total synthesis of biologically active compounds by taking the advantages of high functionalization ability of chiral synthon.

Selective conversion of primary amides to esters promoted by KHSO4

Primary amides, either aliphatic or aromatic, are easily converted to the corresponding esters via reflux in lower primary alcohols in the presence of KHSO4. Secondary amides lead to complicated mixtures under analogous conditions, whereastertiary amides were inert. Use of isopropyl alcohol resulted inthe formation of product atslower rate and lower yieldalong withside products, whereas, use of tertiary alcoholsdid not give successful conversion andallyl and benzyl alcohol provided complex mixtures.

Therapeutic use of isomeric forms of 2-(4-chlorophenyl)quinolin-4-yl)(piperidin-2-yl)methanol

The present invention relates to certain isomeric forms of the 2,4-disubstituted quinoline derivative Vacquinol-1 (NSC13316, (2-(4-chlorophenyl)quinolin-4-yl)(piperidin-2-yl)methanol), for use the in treatment of systemic cancer, as well as pharmaceutical compositions comprising said isomeric forms of the 2,4-disubstituted quinoline derivative Vacquinol-1 for the intended use.

Aryne-Mediated [2,3]-Sigmatropic Rearrangement of Tertiary Allylic Amines

A new strategy has been established for the [2,3]-sigmatropic rearrangement of quaternary allylic ammonium ylides via in situ activation of tertiary allylic amines with arynes under mild conditions. Using 2-(trimethylsilyl)aryl triflates as aryne precurso

COMPOUNDS AND USE FOR TREATING CANCER

The present invention relates to certain 2,4-disubstituted quinoline derivatives, to their therapy, as well as to pharmaceutical compositions comprising said compounds. More specifically the invention relates to certain 2,4-disubstituted quinoline derivatives or pharmaceutical compositions comprising said compounds for the treatment of cancers characterized by overactive Ras and/or Rac or signalling pathway.

SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS

Disclosed are spiro compounds of formula (I), or stereomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used to treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore disclosed are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions in the treatment of HCV infection or hepatitis C disease.